

CITATION REPORT

List of articles citing

Inhibition and induction of cytochrome P450 and the clinical implications

DOI: 10.2165/00003088-199835050-00003
Clinical Pharmacokinetics, 1998, 35, 361-90.

Source: <https://exaly.com/paper-pdf/29424318/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
616	Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. 1999 , 24, 87-92		82
615	Potential interaction between itraconazole and clarithromycin. 1999 , 19, 1439-44		9
614	Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. 1999 , 20, 432-8		32
613	Cytochrome P450 3. Clinically Significant Drug Interactions. 2000 , 30, 146-149		5
612	Differential impairment of triazolam and zolpidem clearance by ritonavir. 2000 , 24, 129-36		43
611	Dose staggering as a strategy to reduce drug--drug interactions due to reversible enzyme inhibition between orally administered drugs with high first pass effect: a computer simulation study. 2000 , 21, 249-59		7
610	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. 2000 , 49, 343-51		75
609	Nonspecific binding of drugs to human liver microsomes. 2000 , 49, 453-61		116
608	Relevance of cytochrome P450 levels in the actions of enflurane and isoflurane in mice: studies on the haem pathway. 2000 , 27, 796-800		3
607	Modulation of oral bioavailability of anticancer drugs: from mouse to man. 2000 , 12, 103-10		112
606	Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. 2000 , 18, 2301-8		84
605	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. 2000 , 24, 129-136		59
604	A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. 2000 , 44, 1832-7		35
603	High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. 2000 , 40, 133-57		245
602	Methyl Sulfone and Hydroxylated Metabolites of Polychlorinated Biphenyls. 2000 , 315-359		82
601	Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 41-57	6.2	623
600	Pharmacokinetic considerations in the eradication of <i>Helicobacter pylori</i> . <i>Clinical Pharmacokinetics</i> , 2000 , 38, 243-70	6.2	76

599	Clinically significant pharmacokinetic interactions between dietary caffeine and medications. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 127-53	6.2	207
598	Assessment of drug-drug interactions: concepts and approaches. 2001 , 31, 499-538		55
597	Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 631-40	6.2	17
596	Interindividual variability in inhibition and induction of cytochrome P450 enzymes. 2001 , 41, 535-67		216
595	Indications for the involvement of a CYP3A-like iso-enzyme in the metabolism of chlorobornane (Toxaphene) congeners in seals from inhibition studies with liver microsomes. 2001 , 51, 319-33		28
594	An approach to the use of antihypertensive drugs in children and adolescents. 2001 , 62, 329-350		11
593	Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. 2001 , 24, 1263-6		17
592	Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. 2001 , 41, 305-16		8
591	Interaction of cimetidine with equine hemoglobin. 2001 , 24, 299-302		
590	Screening of drug candidates for their drug--drug interaction potential. 2001 , 5, 396-401		74
589	Role of drug metabolism in drug discovery and development. 2001 , 21, 397-411		136
588	Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. 2001 , 18, 652-5		91
587	A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. 2001 , 28, 211-30		29
586	Drug metabolism and drug interactions in the elderly. 2001 , 15, 897-918		80
585	High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. 2001 , 31, 557-89		90
584	Antidepressant Drug Interactions. 2001 , 14, 467-477		2
583	Evaluation of 7-benzyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4-trifluoromethylcoumarin derivatives and 7-benzyloxyquinoline as fluorescent substrates for rat hepatic cytochrome P450 enzymes. 2001 , 31, 861-78		22
582	Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. 2001 , 6, 91-9		23

581	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. 2001 , 41, 85-91	88
580	(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. 2002 , 30, 235-9	83
579	The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. 2002 , 30, 349-53	61
578	Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation. 2002 , 86, 630-5	5
577	Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. 2002 , 7, 516-30	96
576	Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). 2002 , 7, 373-82	59
575	In vitro studies in drug discovery and development: an analysis of study objectives and application of good laboratory practices (GLP). 2002 , 34, 679-89	16
574	Antiepileptic-antipsychotic drug interactions: a critical review of the evidence. 2002 , 25, 280-9	18
573	Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. 2002 , 24, 338-45	38
572	Effect of probucol on cytochrome P450 activities in human liver microsomes. 2002 , 25, 1112-4	9
571	Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. 2002 , 25, 383-5	60
570	Effects of Wu-chu-yu-tang and its component herbs on drug-metabolizing enzymes. 2002 , 89, 267-73	22
569	Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. 2002 , 34, 17-35	139
568	Cytochrome P450 polymorphisms and response to antipsychotic therapy. 2002 , 3, 201-18	46
567	Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. 2002 , 8, 293-308	61
566	In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. 2002 , 32, 949-62	18
565	Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. 2002 , 32, 849-62	57
564	Clinically significant interactions with drugs used in the treatment of tuberculosis. 2002 , 25, 111-33	68

563	Mechanisms of clinically relevant drug interactions associated with tacrolimus. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 813-51	6.2	217
562	Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 959-98	6.2	200
561	Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. 2002 , 16, 229-47		52
560	Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. 2002 , 26, 699-703		23
559	Interacciones relevantes de los fármacos metabolizados por el sistema P-450. 2002 , 9, 432-439		
558	Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. 2002 , 35, 261-9		15
557	Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. 2002 , 139, 1-21		412
556	Characterization of quinidine 3-hydroxylation as a probe for the CYP 3A enzyme using a novel capillary electrophoresis technique. 2002 , 16, 265-72		12
555	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. 2002 , 23, 361-7		25
554	Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. 2002 , 27, 281-7		28
553	In vitro tests for predicting drug-drug interactions: the need for validated procedures. 2002 , 91, 209-17		27
552	Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. 2002 , 4, E25		64
551	Drug-phytochemical interactions. 2003 , 11, 7-42		13
550	Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. 2003 , 55, 53-81		256
549	Hepatic microsomal cytochrome P450 enzyme activity in relation to in vitro metabolism/inhibition of polychlorinated biphenyls and testosterone in Baltic grey seal (<i>Halichoerus grypus</i>). 2003 , 22, 636-644		26
548	Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. 2003 , 270, 3768-77		20
547	Metabolic drug interactions with new psychotropic agents. 2003 , 17, 517-38		138
546	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. 2003 , 55, 86-93		36

545	The effect of a strongly basic alkaloidal fraction of <i>Rhazya stricta</i> , a traditional medicinal plant, on cytochrome P450-mediated metabolism of theophylline in mice. 2003 , 17, 688-90		2
544	Interactions of herbs with cytochrome P450. 2003 , 35, 35-98		320
543	Role of P-glycoprotein in pharmacokinetics: clinical implications. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 59-98		593
542	Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 153-78	6.2	97
541	Factors affecting the clinical development of cytochrome p450 3A substrates. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 969-84	6.2	44
540	Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. 2003 , 63, 2739-54		122
539	Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. 2003 , 114, 135-41		150
538	Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. 2003 , 27, 85-102		425
537	Xenobiotic conjugation systems in deer compared with cattle and rat. 2003 , 134, 169-73		7
536	Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. 2003 , 33, 511-27		66
535	Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. 2003 , 31, 282-8		84
534	Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. 2003 , 31, 345-50		81
533	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. 2003 , 31, 861-9		78
532	Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome p4501A2. 2003 , 33, 603-13		41
531	Pharmacogenomic considerations in drug delivery. 2003 , 4, 443-61		10
530	Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. 2003 , 31, 476-81		42
529	Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. 2003 , 18, 128-38		38
528	Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. 2003 , 33, 1201-10		4

527	Determination of the human cytochrome P450s involved in the metabolism of 2n-propylquinoline. 2003 , 33, 341-55	12
526	Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. 2003 , 33, 643-54	6
525	Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. 2003 , 43, 414-22	45
524	Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. 2003 , 18, 121-7	21
523	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. 2004 , 311, 996-1007	76
522	Differential regulation of the human CYP3A4 promoter in transgenic mice and rats. 2004 , 32, 163-7	10
521	Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. 2004 , 34, 415-27	48
520	Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection. 2004 , 311, 307-14	6
519	Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. 2004 , 34, 633-64	54
518	Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. 2004 , 95, 520-9	65
517	In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. 2004 , 95, 144-52	21
516	The pharmacogenomics of selective serotonin reuptake inhibitors. 2004 , 4, 233-44	57
515	Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. 2004 , 487, 183-97	77
514	Novel inhibitors of fatty acid oxidation as potential metabolic modulators. 2004 , 14, 973-7	6
513	Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. 2004 , 16, 79-85	57
512	Simultaneous determination of dexamethasone and 6 beta-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity. 2004 , 804, 421-9	15
511	A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans. 2004 , 14, 689-93	82
510	Lack of an inducible effect of dietary soy isoflavones on the mRNA abundance of hepatic cytochrome P-450 isozymes in rats. 2004 , 68, 508-15	22

509	Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. 2004 , 32, 584-6	24
508	Mechanisms in pulmonary toxicology. 2004 , 25, 1-14	29
507	Identification of variable amino acids in the SRS1 region of CYP6B1 modulating furanocoumarin metabolism. 2004 , 422, 31-41	32
506	Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. 2004 , 424, 226-34	52
505	Identification of UGT2B9*2 and UGT2B33 isolated from female rhesus monkey liver. 2004 , 426, 55-62	3
504	The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. 2004 , 11, 206-12	70
503	Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. 2004 , 19, 55-61	31
502	Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: minimization of mechanism-based CYP3A4 inhibition. 2005 , 53, 1314-7	2
501	Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. 2005 , 28, 1805-8	184
500	Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. 2005 , 28, 1813-6	43
499	No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug. 2005 , 28, 188-91	15
498	Induction of endogenous pathways by antiepileptics and clinical implications. 2005 , 19, 511-29	24
497	A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. 2005 , 30, 21-37	24
496	Assessment of CYP1A2 activity in clinical practice: why, how, and when?. 2005 , 97, 125-34	185
495	Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. 2005 , 26, 737-44	21
494	Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramidate is irreversible and mechanism-based. 2005 , 69, 517-24	33
493	High throughput P450 inhibition screens in early drug discovery. 2005 , 10, 1443-50	80
492	Keynote review: histamine H3 receptor antagonists reach out for the clinic. 2005 , 10, 1613-27	190

491	Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. 2005 , 26, 59-65	13
490	Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. 2005 , 61, 755-61	40
489	Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats. 2005 , 30, 195-201	6
488	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. 2005 , 30, 275-86	22
487	Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. 2005 , 312, 926-37	35
486	Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. 2005 , 33, 349-58	24
485	Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. 2005 , 33, 1637-47	93
484	Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. 2005 , 11, 1608-17	57
483	Development and validation of a high-throughput radiometric cyp2c9 inhibition assay using tritiated diclofenac. 2005 , 33, 359-64	15
482	Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. 2005 , 35, 549-60	17
481	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. 2005 , 23, 1061-9	67
480	QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. 2005 , 39, 543-6	36
479	Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. 2005 , 33, 879-83	37
478	Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors. 2005 , 10, 197-205	65
477	Enhancement of nifedipine-induced gingival overgrowth by concomitant ketoconazole in rats. 2005 , 74, 45-50	
476	Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. 2005 , 33, 853-61	73
475	17 LC/MS application in high-throughput adme screen. 2005 , 413-446	1
474	Autoregulated, bidirectional and multicistronic gas-inducible mammalian as well as lentiviral expression vectors. 2005 , 120, 83-98	21

473	Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies. 2005 , 33, 1613-20		48
472	Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?. 2005 , 33, 603-13		83
471	Effects of repeated administration with CP-55,940, a cannabinoid CB1 receptor agonist on the metabolism of the hepatic heme. 2005 , 37, 1620-5		4
470	Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. 2005 , 19, 275-87		53
469	The influence of age and sex on the clearance of cytochrome P450 3A substrates. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 33-60	6.2	215
468	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 279-304	6.2	349
467	The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1179-89	6.2	53
466	Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. 2005 , 14, 223-41		60
465	Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters. 2005 , 2, 891-908		29
464	Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). 2006 , 34, 1063-9		47
463	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. 2006 , 29, 735-68		64
462	Immunosuppressive effects of rutaecarpine in female BALB/c mice. 2006 , 164, 155-66		19
461	Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. 2006 , 20, 187-210		694
460	Alkamides from <i>Piper nigrum</i> L. and Their Inhibitory Activity against Human Liver Microsomal Cytochrome P450 2D6 (CYP2D6). 2006 , 1, 1934578X0600100		4
459	Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. 2006 , 29, 1931-5		7
458	The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. 2006 , 46, 103-8		17
457	Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. 2006 , 16, 79-86		18
456	Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. 2006 , 12, 97-106		26

455	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. 2006 , 61, 570-84	58
454	Drug interactions in cancer therapy. 2006 , 6, 546-58	224
453	An efficient and convergent synthesis of the potent and selective H3 antagonist ABT-239. 2006 , 62, 4584-4589	16
452	Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics. 2006 , 7, 99-106	11
451	CYP induction-mediated drug interactions: in vitro assessment and clinical implications. 2006 , 23, 1089-116	222
450	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectedin), a novel marine anti-cancer drug. 2006 , 24, 3-14	33
449	A toxicity and hazard assessment of fourteen pharmaceuticals to <i>Xenopus laevis</i> larvae. 2006 , 15, 647-56	88
448	Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. 2006 , 26, 1730-44	217
447	Quantification of the expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-PCR. 2005 , 19, 368-78	30
446	Antidepressant-drug interactions are potentially but rarely clinically significant. 2006 , 31, 1594-604; discussion 1614-5	27
445	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. 2006 , 34, 734-7	38
444	Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. 2006 , 34, 261-6	93
443	Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. 2006 , 34, 783-5	20
442	Transporter-mediated drug interactions: clinical implications and in vitro assessment. 2007 , 3, 81-92	76
441	Induction of phase I and II drug metabolism in rat small intestine and colon in vitro. 2007 , 35, 898-907	31
440	Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. 2007 , 35, 1232-8	61
439	High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. 2007 , 35, 1737-43	13
438	Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. 2007 , 35, 275-82	28

437	Effect of benidipine on simvastatin metabolism in human liver microsomes. 2007 , 22, 199-205	3
436	Stereoselectivity in drug metabolism. 2007 , 3, 149-58	95
435	Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. 2007 , 35, 841-7	7
434	Pharmacokinetics and toxicokinetics: fundamentals and applications in toxicology. 2007 , 25-41	2
433	Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?. 2007 , 35, 2159-65	28
432	Chapter 5 Linear Quantitative Structure-Activity Relationships for the Interaction of Small Molecules with Human Cytochrome P450 Isoenzymes. 2007 , 63-81	2
431	Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. 2007 , 127, 209-16	40
430	Changes in the expression of cytochrome P450 genes in hemin-induced differentiated K562 cells. 2007 , 30, 1954-7	1
429	Drug interactions with herbal medicines. 2007 , 29, 679-86	68
428	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. 2007 , 29, 687-710	265
427	Preventing drug interactions with antidepressants in the elderly. 2007 , 3, 231-243	
426	Induction of CYP2B and CYP2E1 in precision-cut rat liver slices cultured in defined medium. 2007 , 21, 109-15	15
425	Effect of Solanum trilobatum on hepatic drug metabolising enzymes during diethylnitrosamine-induced hepatocarcinogenesis promoted by Phenobarbital in rat. 2007 , 37, 35-49	5
424	Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. 2007 , 47, 871-6	35
423	Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. 2007 , 39, 159-234	575
422	Cytochrome P450: Another Player in the Myocardial Infarction Game?. 2007 , 229-280	
421	Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. 2007 , 55, 10162-7	31
420	In Vitro Studies of Drug Metabolism. 2007 , 231-257	8

419	Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo. 2007 , 14, 1043-51	85
418	Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). 2007 , 17, 2171-8	8
417	Metabolic drug interactions with newer antipsychotics: a comparative review. 2007 , 100, 4-22	198
416	Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. 2007 , 168, 30-50	112
415	Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?. 2007 , 168, 51-65	67
414	Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. 2007 , 31, 232-41	27
413	Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. 2007 , 63, 1031-8	16
412	Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. 2007 , 21, 559-73	54
411	Metabolization of porphyrinogenic agents in brain: involvement of the phase I drug metabolizing system. A comparative study in liver and kidney. 2007 , 27, 717-29	11
410	Urinary profile of 6 beta-hydroxycortisol in workers exposed to aluminum. 2007 , 120, 36-41	1
409	The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. 2008 , 25, 1891-901	93
408	Inhibition and induction of human cytochrome P450 enzymes: current status. 2008 , 82, 667-715	410
407	In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 2008 , 378, 335-43	10
406	Effects of Sairei-to on the pharmacokinetics of nifedipine in rats. 2008 , 22, 12-7	3
405	Cancer phytotherapeutics: role for flavonoids at the cellular level. 2008 , 22, 567-77	117
404	Induction of drug metabolism: species differences and toxicological relevance. 2008 , 254, 184-91	106
403	Generation of a set of simple, interpretable ADMET rules of thumb. 2008 , 51, 817-34	674
402	Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 383-97	6.2 30

401	General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 669-80	6.2	73
400	The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. 2008 , 51, 5423-30		36
399	Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. 2008 , 38, 465-81		47
398	Effect of Danggui and Honghua on Cytochrome P450 1A2, 2C11, 2E1 and 3A1 mRNA Expression in Liver of Rats. 2008 , 36, 1071-81		12
397	Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. 2008 , 112, 179-85		17
396	Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 2008 , 30, 1206-27		269
395	Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. 2008 , 86, 232-9		4
394	Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes. 2008 , 36, 46-50		8
393	Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. 2008 , 36, 604-13		69
392	The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. 2008 , 4, 151-64		15
391	Blood monocyte-derived neohepatocytes as in vitro test system for drug metabolism. 2008 , 36, 1922-9		23
390	Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. 2008 , 36, 1670-8		28
389	An update on metabolism studies using human hepatocytes in primary culture. 2008 , 4, 837-54		59
388	CYP2C75-involved autoinduction of metabolism in rhesus monkeys of methyl 3-chloro-3'-fluoro-4'-((1R)-1-[(1-(trifluoroacetyl)amino]cyclopropyl)carbonyl)amino]ethyl)-1,1'-biphenyl-2-carboxylate (MK-0686), a bradykinin B1 receptor antagonist. 2008 , 325, 935-46		
387	Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. 2008 , 36, 2261-9		24
386	Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. 2008 , 31, 1911-6		11
385	Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. 2008 , 128, 1459-65		9
384	Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107		

383	Modulating temporal and spatial oxygenation over adherent cellular cultures. 2009 , 4, e6891	63
382	Antibodies as a probe in cytochrome P450 research. 2009 , 37, 925-31	11
381	Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. 2009 , 37, 1598-603	29
380	Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. 2009 , 39, 415-22	28
379	Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. 2009 , 37, 1172-8	51
378	Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. 2009 , 24, 261-8	11
377	Pharmacogenomics of CYP3A: considerations for HIV treatment. 2009 , 10, 1323-39	36
376	The histamine H3 receptor as a therapeutic drug target for CNS disorders. 2009 , 14, 509-15	150
375	Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. 2009 , 36, 175-91	87
374	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. 2009 , 36, 565-71	20
373	Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. 2009 , 4, 680-6	129
372	Mechanisms underlying the inhibition of the cytochrome P450 system by copper ions. 2009 , 29, 695-702	29
371	Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. 2009 , 9, 21-8	40
370	Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. 2009 , 35, 603-12	48
369	Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. 2009 , 35, 417-29	22
368	Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. 2009 , 85, 319-26	26
367	Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis. 2009 , 19, 4647-51	41
366	Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. 2009 , 19, 6176-80	27

365	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. 2009 , 5, 579-605	25
364	Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. 2009 , 6, 1662-77	57
363	Disorder of Cytochrome P450 expression is inducible by gold nanoparticles?. 2009 , 2, 184-185	
362	Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3. 2009 , 126, 119-26	28
361	QSAR of cytochrome inhibitors. 2009 , 5, 1245-66	30
360	Drug-drug noninteractions. 2009 , 27, 226-9	5
359	Drug interactions in transplant patients: what everyone should know. 2009 , 18, 404-11	49
358	Azole antimycotics and drug interactions in the perioperative period. 2010 , 23, 441-8	4
357	Drug interaction studies on new drug applications: current situations and regulatory views in Japan. 2010 , 25, 3-15	12
356	Theoretical considerations on quantitative prediction of drug-drug interactions. 2010 , 25, 48-61	20
355	Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. 2006 , 58, 871-85	80
354	Cell based approaches for evaluation of drug-induced liver injury. 2010 , 268, 125-31	70
353	Polymorphisms of human cytochrome P450 2C9 and the functional relevance. 2010 , 278, 165-88	94
352	Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. 2010 , 125, 230-48	70
351	Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists. 2010 , 20, 5165-9	8
350	Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. 2010 , 20, 6231-6	39
349	Effects of matrine and oxymatrine on catalytic activity of cytochrome p450s in rats. 2010 , 107, 906-13	14
348	Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice. 2010 , 268, 540-8	16

347	Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemo-naïve breast cancer patients. 2010 , 21, 2175-2182	18
346	Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. 2010 , 333, 650-62	35
345	Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems. 2010 , 5, 491-511	5
344	Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential. 2010 , 38, 2259-65	11
343	Intervención psiquiátrica en programa de trasplantes. 2010 , 21, 286-292	1
342	Prediction of Pharmacokinetics and Drug Safety in Humans. 2010 , 89-130	
341	Herb-drug pharmacokinetic interactions reviewed. 2010 , 6, 1515-38	56
340	Possible removal of topiramate by continuous renal replacement therapy. 2010 , 288, 186-9	6
339	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. 2010 , 6, 1215-30	10
338	Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. 2010 , 53, 6445-56	19
337	Hepatic stem cells and liver development. 2010 , 640, 181-236	20
336	Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. 2011 , 39, 1022-30	42
335	Cardiovascular Pharmacological Actions of Rutaecarpine, a Quinazolinocarboline Alkaloid Isolated From <i>Evodia rutaecarpa</i> . 2011 , 3, 63-69	8
334	Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. 2011 , 8, 721-34	31
333	Drug Metabolism in Gastrointestinal Tract. 2011 , 91-109	2
332	Once-daily tiroprium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. 2011 , 28, 151-60	12
331	Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. 2011 , 100, 217-36	4
330	Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. 2011 , 7, 1547-60	3

329	Prediction of variability in CYP3A4 induction using a combined 1H NMR metabonomics and targeted UPLC-MS approach. 2011 , 10, 2807-16	17
328	In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats. 2011 , 115, 399-407	9
327	Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. 2011 , 90, 666-73	68
326	Pharmacogenetics of antidepressants. 2011 , 2, 6	55
325	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. 2011 , 75, 585-91	87
324	Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. 2011 , 89, 579-86	44
323	Warfarin Drug Interactions: Strategies to Minimize Adverse Drug Events. 2011 , 7, 506-512	2
322	Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions. 2011 , 36, 879-85	12
321	Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-450 1A2. 2011 , 30, 447-56	26
320	Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. 2011 , 67, 783-90	4
319	Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. 2011 , 108, 2932-40	11
318	Cytochrome P450 2D6 inhibitory constituents of <i>Lunasia amara</i> . 2011 , 4, 30-33	7
317	Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. 2011 , 63, 243-67	81
316	Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. 2011 , 39, 1139-48	34
315	Sex differences in drug disposition. 2011 , 2011, 187103	158
314	Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. 2011 , 16, 903-9	24
313	Cytochrome P450-mediated cardiovascular drug interactions. 2011 , 7, 1065-82	21
312	CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. 2011 , 21, 93-99	14

311	Pharmacogenetics of antidepressant response. 2011 , 36, 87-113	112
310	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. 2011 , 13, 509-16	82
309	Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats. 2012 , 42, 1058-68	10
308	Metabolic difference of CZ48 in human and mouse liver microsomes. 2012 , 13, 5498-505	4
307	Structure-activity relationship modeling for predicting interactions with pregnane X receptor by recursive partitioning. 2012 , 27, 506-12	4
306	Toxic hepatitis in occupational exposure to solvents. 2012 , 18, 2756-66	90
305	Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. 2012 , 40, 1336-44	14
304	Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. 2012 , 42, 854-62	46
303	Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. 2012 , 40, 1178-82	23
302	Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. 2012 , 91, 846-55	33
301	Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. 2012 , 5, 31-42	15
300	ADME of biologics-what have we learned from small molecules?. 2012 , 14, 410-9	41
299	Safety monitoring of herb-drug interactions: a component of pharmacovigilance. 2012 , 35, 785-91	31
298	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. 2012 , 165, 2787-98	59
297	Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. 2012 , 180, 2527-35	19
296	Modulatory effects of Kaempferia parviflora extract on mouse hepatic cytochrome P450 enzymes. 2012 , 141, 831-9	17
295	Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors. 2012 , 22, 4998-5002	20
294	The right compound in the right assay at the right time: an integrated discovery DMPK strategy. 2012 , 44, 224-52	39

293	Toxicity. 2012 , 159-208	
292	Large-scale prediction of drug-target interactions using protein sequences and drug topological structures. 2012 , 752, 1-10	71
291	Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β -adrenoceptor agonist. 2012 , 42, 957-67	39
290	Cytochrome P450 Pharmacogenetics: From Bench to bedside. 2012 , 1-17	
289	Pharmacogenetics of antidepressants and mood stabilizers. 2012 , 106, 715-44	8
288	Effects of <i>Phyllanthus amarus</i> on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. 2012 , 42, 641-8	5
287	Reaction Phenotyping. 2012 , 189-212	1
286	Factors affecting chemical toxicity. 2012 , 48-61	0
285	Cytochrome P450-endogenous substrates metabolism is reduced in patients with a multiple organ dysfunction after coronary artery bypass grafting. 2012 , 4, 9-14	0
284	Discovery of a potent thiazole class of histamine h3 receptor antagonist for the treatment of diabetes. 2012 , 3, 198-202	19
283	Clinically relevant drug interactions in anxiety disorders. 2012 , 27, 239-53	28
282	Synthesis and preliminary pharmacological investigation of new N-substituted-N-[4-(4-phenoxy-alkyl)piperazin-1-yl]alkyl]guanidines as non-imidazole histamine H(3) antagonists. 2012 , 345, 431-43	3
281	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. 2012 , 55, 4896-933	142
280	Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. 2012 , 198, 49-56	26
279	Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists. 2012 , 22, 2075-8	5
278	Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. 2012 , 69, 229-37	11
277	Study of the upregulation of the activity of cytochrome P450 3A isoforms by Astragalus injection and Astragalus granules in rats and in cells. 2013 , 38, 105-13	9
276	Characterization of acetylcholinesterase inhibition and energy allocation in <i>Daphnia magna</i> exposed to carbaryl. 2013 , 98, 28-35	30

275	Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. 2013 , 33, 727-36	65
274	Clinically Relevant Drug-Drug and Drug-Food Interactions. 2013 , 27, 9-23	7
273	How pre-marketing data can be used for predicting the weight of drug interactions in clinical practice. 2013 , 24, 217-21	1
272	Drug interactions result from a number of underlying pharmacokinetic and pharmacodynamic mechanisms. 2013 , 29, 217-222	2
271	Non-imidazole histamine H ligands: part V. synthesis and preliminary pharmacological investigation of 1-[2-thiazol-4-yl- and 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-propylpiperazine derivatives. 2013 , 22, 3640-3652	2
270	Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. 2013 , 41, 50-9	46
269	From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan. 2013 , 107, 258-265	7
268	Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). 2013 , 10, e177-89	47
267	Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes. 2013 , 41, 159-69	7
266	Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. 2013 , 69, 439-48	20
265	A fast and reliable reversed phase high performance liquid chromatography method for simultaneous determination of selected anti-retroviral and lumefantrine in human plasma. 2013 , 919-920, 52-60	12
264	How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation?. 2013 , 19, 7361-9	30
263	Importance of H-abstraction in the final step of nitrosoalkane formation in the mechanism-based inactivation of cytochrome P450 by amine-containing drugs. 2013 , 14, 24692-705	19
262	Effect of three polyether ionophores on pharmacokinetics of florfenicol in male broilers. 2013 , 36, 494-501	17
261	Effect of deuteration on the metabolism and clearance of some pharmacologically active compounds--synthesis and in vitro metabolism of deuterated derivatives of dronedarone. 2013 , 56, 504-12	8
260	Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. 2013 , 41, 2066-75	17
259	Strategies for the Identification of Unusual and Novel Metabolites Using Derivatization, Hydrogen/Deuterium Exchange (HDX), and Liquid Chromatography-nuclear Magnetic Resonance (LC-NMR) Spectroscopy Techniques. 2014 , 1-27	
258	Minor and Short-Acting Analgesics, Including Opioid Combination Products. 2014 , 508-529.e6	3

257	Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. 2014 , 8, 046001	1
256	Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. 2014 , 25, 832-40	9
255	Drugs and the Elderly. 2014 , 639-658	0
254	First evidence for toxic defense based on the multixenobiotic resistance (MXR) mechanism in <i>Daphnia magna</i> . 2014 , 148, 139-51	37
253	Pharmacokinetic interaction of enrofloxacin/trimethoprim combination following single-dose intraperitoneal and oral administration in rats. 2014 , 39, 11-6	1
252	A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS. 2014 , 64, 9.18.1-10	1
251	An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes. 2014 , 4, 270-278	14
250	Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene. 2014 , 6, 482-91	5
249	A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. 2014 , 101, 221-37	72
248	Herb-drug interactions: challenges and opportunities for improved predictions. 2014 , 42, 301-17	113
247	Effect of simvastatin and naringenin coadministration on rat liver DNA fragmentation and cytochrome P450 activity: an in vivo and in vitro study. 2014 , 70, 225-37	17
246	Comparison of liquid chromatography and supercritical fluid chromatography coupled to compact single quadrupole mass spectrometer for targeted in vitro metabolism assay. 2014 , 1371, 244-56	37
245	Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. 2014 , 42, 1617-26	20
244	In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies. 2014 , 62, 10604-14	7
243	A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data. 2014 , 42, 1587-95	19
242	Hepatic organoids for microfluidic drug screening. 2014 , 14, 3290-9	106
241	How should we regulate risk in biomedical research? An ethical analysis of recent policy proposals and initiatives. 2014 , 117, 409-20	8
240	In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. 2015 , 8, 914-918	10

239	Dealing with the complex drug-drug interactions: towards mechanistic models. 2015 , 36, 71-92		48
238	Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. 2015 , 80, 1097-108		6
237	Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. 2015 , 35, 670-80		29
236	4-Hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. 2015 , 80, 560-8		16
235	Constituents of Indonesian Medicinal Plant Averrhoa bilimbi and Their Cytochrome P450 3A4 and 2D6 Inhibitory Activities. 2015 , 10, 1934578X1501000		
234	Inhibition of Cytochrome P450 Enzymes. 2015 , 177-259		7
233	Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators. 2015 , 25, 1621-6		10
232	A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. 2015 , 43, 1718-26		8
231	Metabolic characterization of meso-dihydroguaiaretic acid in liver microsomes and in mice. 2015 , 76, 94-102		6
230	A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 371-83	6.2	32
229	Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes. 2015 , 45, 131-8		11
228	Selective Optimization of Side Activities (SOSA) in Drug Discovery. 2015 , 473-486		1
227	The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. 2015 , 136, 13-8		15
226	Cardiac contractility in Antarctic teleost is modulated by nitrite through xanthine oxidase and cytochrome p-450 nitrite reductase. 2015 , 49, 1-7		5
225	Benzyne Formation in the Mechanism-Based Inactivation of Cytochrome P450 by 1-Aminobenzotriazole and N-Benzyl-1-Aminobenzotriazole: Computational Insights. 2015 , 5, 2952-2960		11
224	The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. 2015 , 14, 179		29
223	Pharmacokinetics and tissue distribution of the new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy) propyl]piperidine in rats. 2015 , 45, 912-20		3
222	Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. 2015 , 32, 999-1008		54

221	Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A. 2015 , 97, 320-30	12
220	Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. 2015 , 58, 7057-75	14
219	Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems. 2015 , 45, 213-7	7
218	Characterization of equine cytochrome P450: role of CYP3A in the metabolism of diazepam. 2016 , 39, 478-87	5
217	Cytochrome P450 Organization and Function Are Modulated by Endoplasmic Reticulum Phospholipid Heterogeneity. 2016 , 44, 1859-1866	32
216	Atypical profiles and modulations of heme-enzymes catalyzed outcomes by low amounts of diverse additives suggest diffusible radicals' obligatory involvement in such redox reactions. 2016 , 125, 91-111	31
215	Evaluation of the impact of 16-dehydropregnenolone on the activity and expression of rat hepatic cytochrome P450 enzymes. 2016 , 163, 183-92	10
214	Development of pipette tip-based on molecularly imprinted polymer micro-solid phase extraction for selective enantioselective determination of (1)-(2S,4R) and (+)-(2R,4S) ketoconazole in human urine samples prior to HPLC-DAD. 2016 , 8, 4075-4085	23
213	A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?. 2016 , 2, 187-192	13
212	Pharmacokinetic Properties. 2016 , 3-27	0
211	Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents. 2016 , 44, 1608-16	8
210	Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. 2016 , 30, 607-615	
209	Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. 2016 , 6, 28482	23
208	Metabolism-Based Drug-Drug Interactions in Critically Ill Patients: Clinical Relevance and Predictability of In Vitro Systems. 2016 , 1-48	
207	Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. 2016 , 128, 184-190	14
206	Calcitriol-copper interaction leads to non enzymatic, reactive oxygen species mediated DNA breakage and modulation of cellular redox scavengers in hepatocellular carcinoma. 2016 , 21, 997-1007	14
205	Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. 2016 , 389, 211-21	36
204	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. 2016 , 12, 399-406	27

203	Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. 2016 , 44, 343-51	91
202	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. 2016 , 68, 168-241	128
201	CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. 2016 , 16, 88-95	34
200	Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury. 2017 , 47, 290-296	11
199	Gastrointestinal interactions, absorption, splanchnic metabolism and pharmacokinetics of orally ingested phenolic compounds. 2017 , 8, 15-38	93
198	An evaluation of the completeness of drug-drug interaction-related information in package inserts. 2017 , 73, 165-174	2
197	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. 2017 , 55, 71-82	36
196	Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions. 2017 , 177, 67-80	41
195	Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. 2017 , 45, 501-511	10
194	Illuminating cytochrome P450 binding: Ru(II)-caged inhibitors of CYP17A1. 2017 , 53, 3673-3676	49
193	Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation. 2017 , 42, 827-834	6
192	In vitro investigation of metabolic profiling of newly developed topoisomerase inhibitors (ethyl fluorescein hydrazones, EtFLHs) in RLMs by LC-MS/MS. 2017 , 1054, 93-104	4
191	In vitro Investigation of Metabolic Profiling of a Potent Topoisomerase Inhibitors Fluorescein Hydrazones (FLHs) in RLMs by LC-MS/MS. 2017 , 1054, 27-35	2
190	Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. 2017 , 106, 2715-2726	11
189	Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery. 2017 , 106, 2839-2846	8
188	General Pharmacology of Anesthetic and Analgesic Drugs. 2017 , 145-177	
187	Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life. 2017 , 3, 1-9	10
186	Involvement of astrocytic CYP1A1 isoform in the metabolism and toxicity of the alkaloid pyrrolizidine monocrotaline. 2017 , 134, 41-49	3

185	Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. 2017 , 176, 705-713	37
184	Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents. 2017 , 109, 182-190	31
183	Noncompetitive inhibition of human CYP2C9 in vitro by a commercial <i>Rhodiola rosea</i> product. 2017 , 5, e00324	6
182	Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on <i>Comt</i> , <i>Slc6a15</i> and <i>Adora1</i> gene expression. 2017 , 337, 95-103	8
181	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. 2017 , 13, 83-95	21
180	Drug Metabolism in the Liver. 2017 , 21, 1-20	220
179	Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?. 2017 , 118, 82-92	70
178	The challenges of pharmacokinetic variability of first-line anti-TB drugs. 2017 , 10, 47-58	13
177	Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile. 2017 , 8, 771-779	4
176	Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method. 2017 , 31, e3905	2
175	Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. 2018 , 15, 1979-1995	15
174	Drugs for Tuberculosis. 2018 , 221-253	
173	TGF β -mediated suppression of cytochrome P450(CYP) induction responses in rat hepatocyte-fibroblast co-cultures. 2018 , 50, 47-53	2
172	Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles. 2018 , 54, 1280-1290	49
171	Effect of Korean Red Ginseng extracts on drug-drug interactions. 2018 , 42, 370-378	11
170	Allosteric activation of cytochrome P450 3A4 by efavirenz facilitates midazolam binding. 2018 , 48, 1227-1236	5
169	Effects of Herbal Formulas Bojungikgi-tang and Palmijihwang-hwan on Inflammation in RAW 264.7 Cells and the Activities of Drug-Metabolizing Enzymes in Human Hepatic Microsomes. 2018 , 21, 1173-1187	5
168	Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 2018 , 13, 8561-8575	8

167	Assessing HerbDrug Interactions of Herbal Products With Therapeutic Agents for Metabolic Diseases: Analytical and Regulatory Perspectives. 2018 , 59, 283-322	6
166	Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes. 2018 , 43, 737-750	3
165	In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent. 2018 , 160, 202-211	9
164	Review of Major Drug-Drug Interactions in Thoracic Transplantation. 2018 , 5, 220-230	
163	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. 2018 , 11, 113-119	11
162	Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications. 2018 , 18,	78
161	No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. 2018 , 12, 2475-2483	5
160	Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation. 2018 , 31, 548-555	14
159	Time-dependent inhibition (TDI) of CYP1A2 by a CYP3A4-mediated reactive metabolite: proposal for a novel mechanism of irreversible TDI by a non-suicide substrate. 2019 , 49, 636-645	2
158	Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy. 2019 , 90, 3-14	9
157	Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. 2019 , 27, 819-827	8
156	Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study. 2019 , 44, 229-236	5
155	Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. 2019 , 67, 810-815	4
154	Effects of phosphate on drug solubility behavior of mixture ibuprofen and lidocaine. 2019 , 525, 110415	8
153	The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies. 2019 , 15, 921-936	9
152	Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. 2019 , 116, 154-162	11
151	4-(3-Aminoazetid-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H Receptor Agonists with in Vivo Central Nervous System Activity. 2019 , 62, 10848-10866	6
150	Molecular Docking as a Promising Predictive Model for Silver Nanoparticle-Mediated Inhibition of Cytochrome P450 Enzymes. 2019 , 59, 5126-5134	8

149	Induction of Cytochrome P450 Involved in the Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomes In Vivo. 2019 , 47, 364-376	7
148	Safety-Related Quality Issues for the Development of Herbal Drugs. 2019 , 655-683	2
147	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. 2019 , 7, 26	3
146	Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment. 2019 , 172, 206-213	2
145	An assessment of the impact of multi-route co-exposures on human variability in toxicokinetics: A case study with binary and quaternary mixtures of volatile drinking water contaminants. 2019 , 39, 974-991	4
144	Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. 2019 , 33, e13510	19
143	Essential oil components and cytochrome P450 enzymes: a review. 2019 , 34, 223-240	8
142	Pharmacoristance aux psychotropes et anomalies pharmacogñiques du cytochrome P450 2D6: vers une mñdecine personnalisñ en pñopsychiatrie, prñsentation dñn protocole de recherche. 2019 , 67, 109-117	2
141	Virtual screening of natural products as an inhibitor of DNA methyltransferase 1 enzyme for breast cancer disease. 2019 , 509, 012052	
140	Administration of Vitamin D Metabolites Affects RNA Expression of Xenobiotic Metabolising Enzymes and Function of ABC Transporters in Rats. 2019 , 2019, 1-11	1
139	Pre-formulation investigations for establishing a protocol for treosulfan handling and activation. 2019 , 24, 639-648	
138	Time-dependent inhibition of carbamazepine metabolism by piperine in anti-epileptic treatment. 2019 , 218, 314-323	8
137	Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy. 2019 , 165, 115-132	17
136	A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam. 2019 , 59, 7-19	8
135	Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity. 2019 , 44, 423-431	11
134	Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. 2020 , 319, 148-154	16
133	Piperine Is a Mechanism-Based Inactivator of CYP3A. 2020 , 48, 123-134	6
132	A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 447-462	6.2 22

131	Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways. 2020 , 213-236	
130	In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. 2020 , 273-309	
129	Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes. 2020 , 106, 106934	4
128	Cytochrome P450 Expression and Chemical Metabolic Activity before Full Liver Development in Zebrafish. 2020 , 13,	10
127	The influence of phase II enzymes on in vitro half-life of pirydo[1,2-c]pirymidine derivatives as structural analogues of arylpiperazine. 2020 , 159, 105550	
126	No alteration of Cyp3A4 activity after major hepatectomy in the early postoperative period - A prospective before-after study. 2020 , 79, 131-135	3
125	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. 2020 , 180, 1052-1060	16
124	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. 2020 , 108, 191-200	89
123	Water Extract Shows Low Potential for Cytochrome P450-Mediated Drug Interactions. 2020 , 48, 1053-1063	3
122	Inducibility of cytochrome P450-mediated 7-methoxycoumarin-O-demethylase activity in zebrafish (<i>Danio rerio</i>) embryos. 2020 , 225, 105540	4
121	Predicting liver cytosol stability of small molecules. 2020 , 12, 21	8
120	In vitro hepatic biotransformation of the algal toxin pectenotoxin-2. 2020 , 6, 100031	0
119	Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?. 2020 , 16, 387-401	7
118	2-Aminopyridine Analogs Inhibit Both Enzymes of the Glyoxylate Shunt in. 2020 , 21,	0
117	Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (-)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (-)-Sophoranone. 2020 , 12,	2
116	Therapeutic advances of miRNAs: A preclinical and clinical update. 2021 , 28, 127-138	86
115	Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein. 2021 , 61, 298-306	0
114	Herbal remedies, toxicity, and regulations. 2021 , 89-127	1

113	The ADME Encyclopedia. 2021 , 1-11		
112	CHAPTER 11:Strategies to Mitigate CYP450 Inhibition. 2021 , 220-247		
111	Into the Fray! A Beginner's Guide to Medicinal Chemistry. 2021 , 16, 1199-1225		1
110	Paroxetine-Overview of the Molecular Mechanisms of Action. 2021 , 22,		4
109	Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 585-601	6.2	9
108	Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights. 2021 , 34, 959-987		2
107	Current perspectives in herbal and conventional drug interactions based on clinical manifestations. 2021 , 7,		0
106	[Pharmacoresistance to psychotropic drugs in children and adolescents: Pharmacogenetic anomalies of cytochrome P450 2D6]. 2021 , 47, 227-234		
105	Generation of Budding-Like Intestinal Organoids from Human Induced Pluripotent Stem Cells. 2021 , 110, 2637-2650		2
104	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. 2021 , 19, 2068-2081		5
103	Overcoming the Pregnane X Receptor Liability: Rational Design to Eliminate PXR-Mediated CYP Induction. 2021 , 12, 1396-1404		0
102	Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. 2021 , 110, 1526-1536		6
101	Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review. 2021 , 17, 927-949		3
100	Comprehensive Investigation of Stereoselective Food Drug Interaction Potential of Resveratrol on Nine P450 and Six UGT Isoforms in Human Liver Microsomes. 2021 , 13,		0
99	llexsaponin A1: In vitro metabolites identification and evaluation of inhibitory drug-drug interactions. 2021 , 40, 100415		
98	Cytochrome P450 Inhibition Assay Using Human Liver Microsomes. 2021 , 91-105		
97	Drug Interactions. 344-359		2
96	Pharmacogenetics of Antidepressant Response. 2008 , 315-353		1

95	Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective. 2010 , 585-624	3
94	Pharmacology and Therapeutic Hypothermia. 2012 , 87-99	1
93	Drug Interactions in Solid Organ Transplant Recipients. 2014 , 411-425	1
92	Mechanisms of Drug Interactions. 2001 , 13-38	3
91	Drugs for Tuberculosis. 2001 , 109-120	3
90	In vitro assays for induction of drug metabolism. 2009 , 481, 47-58	21
89	The Emerging Significance of Drug Transporters and Metabolizing Enzymes to Ophthalmic Drug Design. 2008 , 375-397	2
88	Drugs for Tuberculosis. 2011 , 401-424	1
87	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. 2011 , 11-41	1
86	CYP Time-Dependent Inhibition (TDI) Using an IC50 Shift Assay with Stable Isotopic Labeled Substrate Probes to Facilitate Liquid Chromatography/Mass Spectrometry Analyses. 2014 , 315-336	1
85	Molecular Aspects of Histamine Receptors. 2016 , 1-49	3
84	Chronotoxicity of Semen Strychni is associated with circadian metabolism and transport in mice. 2021 , 73, 398-409	3
83	Metabolic basis of drug interactions in the intensive care unit. 2000 , 22, 1-13	7
82	Human cytochromes mediating sertraline biotransformation: seeking attribution. 1999 , 19, 489-93	23
81	Drug Interactions during Anti-Infective Treatments. 1320-1352	2
80	Morning Spot and 24-Hour Urinary 6 β -Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction. 1999 , 39, 487-494	12
79	Methods to Study Bioavailability of Phytochemicals. 2004 , 25-56	3
78	Drug Discovery. 2008 , 103-165	10

77	Depression and anxiety. 2005 , 135-203	2
76	TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. 2013 , 8, e63028	21
75	Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. 2015 , 10, e0143701	15
74	The Inhibitory Effects of Anticancer Drugs Cyclophosphamide, Etoposide and Vincristine on CYP2C19-mediated S-mephenytoin 4'-hydroxylation in Human Liver Microsomes. 2002 , 14, 207-214	2
73	Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. 2005 , 1, 3-13	47
72	Safety Monitoring of Herb-Drug Interactions. 2012 , 35, 785	1
71	Central Histamine, the H-Receptor and Obesity Therapy. 2019 , 18, 516-522	3
70	Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes. 2017 , 25, 288-295	5
69	Effect of Water-miscible Organic Solvents on CYP450-mediated Metoprolol and Imipramine Metabolism in Rat Liver Microsomes. 2015 , 77, 382-90	2
68	Detection of CYP1A1 and GSTP1 gene polymorphisms in bladder cancer patients in a Turkish population using a polymerase chain reaction-restriction fragment length polymorphism method. 2018 , 44, 125-131	1
67	Artificial neural network cascade identifies multi-P450 inhibitors in natural compounds. 2015 , 3, e1524	9
66	Pharmacology. 2002 , 13-35	
65	CYP Gene Induction by Xenobiotics and Drugs. 2003 , 337-374	
64	Alcohol and Drug Interactions. 2004 , 395-462	
63	Drug Disposition and Response. 2004 , 27-42	
62	Polymorphisms in Cardiovascular Medicine. 2006 , 209-242	
61	Drug Discovery Trends. 2006 , 1-32	
60	Minor and Short-Acting Analgesics, Including Opioid Combination Products. 2008 , 613-641	1

59 Obesity. **2008**, 277-304

58 Relevant CYP450-mediated Drug Interactions in the ICU. **2009**, 870-877

3

57 Hepatic Stem Cells and Liver Development. **2009**, 439-469

56 Drug Disposition and Response. **2009**, 27-43

55 Relevant CYP450-mediated Drug Interactions in the ICU. **2009**, 870-877

54 Enzyme Inhibition. 1

53 Interrelationship between Pharmacokinetics and Metabolism. 1

52 Hepatocytes. **2011**, 17-26

51 Nanoparticles for the Oral Administration of Cancer Therapies. **2011**, 487-509

50 Pharmacokinetic and Pharmacodynamic Interactions Between Alcohol and Other Drugs. **2012**, 499-586

49 Drug Interactions and Polypharmacy. **2013**, 45-74

48 Influence of smoking on medication efficacy. **2013**, 276-292

47 Rapidly Distinguishing Reversible and Time-Dependent CYP450 Inhibition Using Human Liver Microsomes, Co-incubation, and Continuous Fluorometric Kinetic Analyses. **2014**, 281-303

46 Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes. **2014**, 269-279

45 ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules. 1-11

44 The use of goldenrod general (*Solidago virgaurea*) preparations does not influence the metabolism of concomitantly administered drugs. **2016**, 30, 5-10

1

43 Gene Level Interactions of Four Commonly Used Herbal Products-A Systematic Literature. **2018**, 18, 307-316

42 Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder. **2018**, 73, 411-419

1

41	Stress Evaluation to Heavy Metal Exposure using Molecular Marker in <i>Chironomus riparius</i> .. 2020 , 53, 165-172	1
40	Induction and Inhibition of Drug-Metabolising Enzymes. 2005 , 209-242	0
39	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. 2020 , 35,	1
38	Interactions between the cytochrome P450 system and the second-generation antipsychotics. 2003 , 28, 99-112	92
37	Drug interactions: a primer for the gastroenterologist. 2012 , 8, 376-83	4
36	Association between CYP19A. 2019 , 8, 162-168	3
35	Cannabis Use and Misuse in Older Adults. 2022 , 38, 67-83	0
34	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.. 2022 , 4, 315-323	1
33	Cytochrome P450 Enzymes and Drug Metabolism in Humans. 2021 , 22,	15
32	Synthesis, molecular modeling, quantum mechanical calculations and ADME estimation studies of benzimidazole-oxadiazole derivatives as potent antifungal agents. 2022 , 1252, 132095	8
31	In silico, ADMET and Docking Analysis for the Compounds of Chloroform Extract of <i>Tinospora cardifolia</i> (Wild.) Identified by GC-MS and Spectral Analysis for Antidiabetic and Anti-Inflammatory Activity. 2022 , 34, 342-354	1
30	Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.. 2022 , 1	0
29	Docking Ligands into Flexible and Solvated Macromolecules. 8. Forming New Bonds-Challenges and Opportunities.. 2022 ,	2
28	In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.. 2022 , 22, 46	0
27	Experimental and modeling evidence supporting the -inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide (OATP) 1B1 by cyclosporine A.. 2022 ,	0
26	Farmacocinética de los medicamentos. 2022 , 26, 1-9	
25	Effect of Mild and Moderate Hepatic Impairment (defined by Child Pugh classification and National Cancer Institute-Organ Dysfunction Working Group criteria) on Pexidartinib Pharmacokinetics.. 2022 ,	0
24	effects of 95% khat ethanol extract (KEE) on human recombinant cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2 and CYP3A5.. 2021 , 37,	4

23	Energy Decomposition Analysis of the Nature of Coordination Bonding at the Heme Iron Center in Cytochrome P450 Inhibition.. 2022 ,		1
22	Interaction of compounds derived from the Chinese medicinal formula Huangqi Guizhi Wuwu Tang with stroke-related numbness and weakness targets: An in-silico docking and molecular dynamics study.. <i>Computers in Biology and Medicine</i> , 2022 , 146, 105568	7	1
21	Combination of Protease Inhibitors for the Treatment of HIV-1-Infected Patients: A Review of Pharmacokinetics and Clinical Experience. 2002 , 6, 201-229		40
20	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. 2022 , 213, S66-S71		1
19	Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System. 2022 , 11, 1677		0
18	Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022 , 3, 100112	3	0
17	Metabolism Drug Interactions. 2022 , 631-641		
16	Twelve-month Treatment Retention and Associated Factors: A Comparison of 2 Medically Assisted Therapy Clinics in Dar es Salaam, Tanzania. <i>Journal of Addiction Medicine</i> , Publish Ahead of Print,	3.8	0
15	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. <i>JAMA Network Open</i> , 2022 , 5, e2219128	10.4	1
14	Interactions of the Protease Inhibitor, Ritonavir, with Common Anesthesia Drugs. <i>Paediatric Anaesthesia</i> ,	1.8	0
13	Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone. <i>Computers in Biology and Medicine</i> , 2022 , 148, 105814	7	0
12	Issues Related to the Treatment of H. pylori Infection in People Living with HIV and Receiving Antiretrovirals. 2022 , 10, 1541		
11	Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects. 2000 , 40, 1274-1279		2
10	Fate of drug-metabolizing enzymes in metabolic diseases. 2022 , 209-230		0
9	Label-free chemical imaging of cytochrome P450 activity by Raman microscopy. 2022 , 5,		0
8	In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA2AR antagonists for the treatment of Parkinson's disease. 2022 ,		0
7	Integrating pharmacogenomics into precision pain management.		1
6	Enzyme Inhibition. 2022 , 407-425		0

5	Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.	1
4	Inhibitory effect of <i>Selaginella doederleinii</i> hieron on human cytochrome P450. 14,	0
3	Generation of Caco-2 cells with predictable metabolism by CYP3A4, UGT1A1 and CES using the PITCh system. 2023 , 50, 100497	0
2	Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4. 2023 , 62, 3305-3320	0
1	Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol. 2023 , 55, 1-49	0